Ensayos clínicos

Inclusion Criteria:

• Age 30-80 years.
• Estimated glomerular filtration rate (eGFR) 25-55 ml/min/1.73m^2.
• Spot urine albumin:creatinine ≥ 30 mg/g unless on RAAS inhibition.
• Ability to give informed consent.

Exclusion Criteria:

• Hemoglobin A1c greater than or equal to 11% (in individuals with diabetes mellitus).
• Anemia (hemoglobin less than 9 g/dL).
• Body weight greater than 150 kg or BMI greater than 50.
• Uncontrolled hypertension: sustained systolic blood pressure (SBP) greater than 155 mmHg at screening exam (a maximum of 3 screening visits will be allowed for demonstration of blood pressure control).
• Chronic hypotension: sustained SBP less than 85 mmHg at screening exam.
• Glomerulonephritis not in partial or complete remission for 6 months (or estimated/ measured proteinuria greater than 10 grams/day),
• Active glomerulonephritis (glomerular diseases) include ANCA-associated glomerulonephritis, post-infectious glomerulonephritis, lupus nephritis, amyloidosis, or other monoclonal gammopathy of renal significance.
• Nephrotic syndrome defined as proteinuria greater than 3.5 g per 24 hours, plus hypoalbuminemia (serum albumin less than or equal to 2.5 g/L) and edema. Autosomal dominant or recessive polycystic kidney disease.
• Kidney failure requiring renal replacement therapy (hemodialysis, peritoneal dialysis, or kidney transplantation).
• Active immunosuppression therapy (including prednisone greater than or equal to 10 mg daily).
• Kidney transplantation history.
• Solid organ transplantation history.
• Recent cardiovascular event (myocardial infarction, stroke, congestive heart failure) within 6 months or uncontrolled cardiac arrhythmias.
• History of liver cirrhosis.
• Chronic obstructive pulmonary disease or asthma requiring daily medication.
• History of blood clotting disorder (thromboembolism; pulmonary embolism, deep venous thrombosis).
• Pregnancy.
• Active malignancy.
• Active infection.
• History of hepatitis B or C (without cure), or HIV infection.
• History of allergic reaction to cellular products (i.e., blood transfusions, platelets).
• Active tobacco use.
• Illicit drug use and excessive alcohol use.
• Presence of psychosocial issues (e.g., uncontrolled mental illness, unpredictable childcare or eldercare responsibilities, irregular/ inflexible work schedule) that may interfere with the ability to complete all study procedures.
• Subjects anticipating prolonged travel or other physical restrictions that would prohibit return for scheduled study visits.
• Inability or unwilling to have magnetic resonance imaging (MRI) or computed tomography (CT) studies.
• Inability to give informed consent.